NCT00506792View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QAU145 in Patients With Cystic Fibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

November 30, 2009

Conditions
Cystic Fibrosis
Interventions
DRUG

QAU145

DRUG

Placebo

Trial Locations (1)

35294-0006

University of Alabama at Birmingham, Birmingham

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY